A5079011531- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Multiple Myeloma Research and Treatments
- Immunodeficiency and Autoimmune Disorders
- Hematopoietic Stem Cell Transplantation
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Eosinophilic Disorders and Syndromes
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Erythrocyte Function and Pathophysiology
- Adolescent and Pediatric Healthcare
- Blood groups and transfusion
- Neutropenia and Cancer Infections
- Histone Deacetylase Inhibitors Research
- Lung Cancer Treatments and Mutations
- Hemoglobinopathies and Related Disorders
- Childhood Cancer Survivors' Quality of Life
- Viral-associated cancers and disorders
- Moyamoya disease diagnosis and treatment
- Neurological Complications and Syndromes
- Drug-Induced Hepatotoxicity and Protection
- Liver physiology and pathology
AstraZeneca (United Kingdom)
2024-2025
Canberra Hospital
2012-2023
ACT Government
2012-2022
Australian National University
2010-2022
Australasian Leukaemia and Lymphoma Group
2004-2020
Australian Cancer Research Foundation
2019
Westmead Hospital
2017
Calvary Mater Newcastle Hospital
2017
Royal North Shore Hospital
2017
Wollongong Hospital
2017
Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and central to the survival of chronic lymphocytic leukemia cells. We evaluated efficacy venetoclax in combination with rituximab patients relapsed or refractory leukemia.In this randomized, open-label, phase 3 trial, we randomly assigned 389 receive for up 2 years (from day 1 cycle 1) plus first 6 months (venetoclax-rituximab group) bendamustine (bendamustine-rituximab group). The trial design did not...
In previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine (BR) patients relapsed or refractory chronic lymphocytic leukemia (CLL). At 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and predictive value molecular genetic characteristics.Patients CLL were randomly assigned 2 years (VenR for first six cycles) cycles BR. PFS, overall (OS),...
The MURANO trial (A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine in Participants Relapsed or Refractory Chronic Lymphocytic Leukemia [CLL]; ClinicalTrials.gov identifier #NCT02005471) reported superior progression-free survival (PFS) and overall (OS) with venetoclax-rituximab (VenR) vs bendamustine-rituximab (BR) relapsed/refractory (R/R) CLL. Patients were randomized 2 years VenR (n = 194; rituximab for first 6 months) months BR 195). Although...
Abstract Sorafenib maintenance improves outcomes after hematopoietic cell transplant (HCT) for patients with FMS-like tyrosine kinase 3–internal tandem duplication (FLT3-ITD) acute myeloid leukemia (AML). Although promising have been reported sorafenib plus intensive chemotherapy, randomized data are limited. This placebo-controlled, phase 2 study (ACTRN12611001112954) 102 (aged 18-65 years) 2:1 to vs placebo (days 4-10) combined induction: idarubicin 12 mg/m2 on days 1 3 either cytarabine...
Abstract Background Single-cell technologies enable the fine mapping of disease and treatment mechanisms in inflammatory bowel (IBD). We sought to leverage these insights discover novel drug targets with precise therapeutic hypotheses. To this end, we previously constructed one largest integrated single-cell atlas IBD patient-derived tissue samples1. then used Immunai’s ImmunoDynamics EngineTM, a proprietary machine learning (ML) framework, identify transcriptional signatures inflammation...
Abstract Reversible posterior encephalopathy (RPES) is an uncommon neurological syndrome that being increasingly reported in association with anti‐neoplastic therapies. The first case of reversible associated the proteosome inhibitor bortezomib described and experience occurrence RPES other antineoplastic therapies reviewed. Dysregulation cerebral vasomotor autoregulation postulated as underlying pathophysiology this RPES.
Dichloroacetate (DCA) is an investigational drug targeting the glycolytic hallmark of cancer by inhibiting pyruvate dehydrogenase kinases (PDK). It metabolized GSTZ1, which has common polymorphisms altering enzyme or promoter activity. GSTZ1 also irreversibly inactivated DCA. In first clinical trial DCA in a hematological malignancy, DiCAM (DiChloroAcetate Myeloma), we have examined relationship between concentrations, genotype, side effects, and patient response. recruited seven myeloma...
Purpose Higher doses of the anthracycline daunorubicin during induction therapy for acute myeloid leukemia (AML) have been shown to improve remission rates and survival. We hypothesized that improvements in outcomes adult AML may be further achieved by increased dose consolidation therapy. Patients Methods with complete after were randomly assigned receive two cycles cytarabine 100 mg/m 2 daily 5 days, etoposide 75 idarubicin 9 either or 3 days (standard intensive arms, respectively). The...
Some patients receiving a tyrosine kinase inhibitor (TKI) for the first-line treatment of chronic phase myeloid leukemia (CML-CP) experience intolerable adverse events. Management strategies include dose adjustments, interrupting or discontinuing therapy, switching to an alternative TKI.This multicenter, single-arm, Phase IIIb study included CML-CP intolerant of, but responsive to, with imatinib dasatinib. All were switched nilotinib 300 mg bid up 24 months. The primary endpoint was...
The setting of chronic immunosuppression in inflammatory bowel disease (IBD) may promote the proliferation Epstein-Barr virus-positive neoplastic clones. We report two rare cases virus-associated lymphoproliferative disorder IBD patients: one resembled lymphomatoid granulomatosis, and other was a lymphoma resembling Hodgkin lymphoma. There are currently no guidelines for prevention patients on immunosuppressive therapy.
Abstract BACKGROUND. Administration of salvage chemotherapy to patients with relapsed or refractory lymphoma is associated significant toxicity. Vinorelbine and gemcitabine are novel chemotherapeutic agents minimal overlapping We present a phase 2 study vinorelbine without ifosfamide administered in an ambulatory care setting for lymphoma. METHODS. Ninety were enrolled. Group 1 comprised “good” risk disease, “high” 3 relapsing after prior stem cell transplant. Patients received filgrastim...
Sorafenib priming may augment salvage chemotherapy in relapsed
Pediatric regimens have improved outcomes in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL). However, results remain inferior to children with ALL. The Australasian Leukaemia Lymphoma Group (ALLG) ALL06 study (anzctr.org.au/ACTRN12611000814976) was designed assess whether a pediatric ALL regimen (Australian New Zealand Children's Haematology Oncology [ANZCHOG] Study 8) could be administered patients aged 15 39 years comparable time frame as assessed by the proportion of...
Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light the imminent vaccination roll out in both countries, representatives all adult paediatric allogeneic bone marrow transplant cellular therapy (TCT) centres as well from autologous only collaborated with infectious diseases specialists expertise TCT on this consensus position statement regarding patients Zealand. It is our recommendation that patients, should expedited access to high-efficacy...